o(6)-benzylguanine has been researched along with Malignant Melanoma in 8 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
| Excerpt | Relevance | Reference |
|---|---|---|
| "1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma." | 9.11 | Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005) |
| " Aim of the present study was to investigate the molecular mechanisms underlying acquired resistance of melanoma cells to TMZ and the effect of O6-benzylguanine (BG), a specific MGMT inhibitor, on the development of a TMZ-resistant phenotype." | 7.73 | A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. ( Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G, 2006) |
| "Fotemustine is a third generation chloroethylnitrosourea that has demonstrated significant antitumoral effects in malignant melanoma." | 7.72 | Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. ( Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Montero, JL; Passagne, I; Vian, L; Winum, JY, 2003) |
| "1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma." | 5.11 | Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005) |
| " Aim of the present study was to investigate the molecular mechanisms underlying acquired resistance of melanoma cells to TMZ and the effect of O6-benzylguanine (BG), a specific MGMT inhibitor, on the development of a TMZ-resistant phenotype." | 3.73 | A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. ( Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G, 2006) |
| "Fotemustine is a third generation chloroethylnitrosourea that has demonstrated significant antitumoral effects in malignant melanoma." | 3.72 | Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. ( Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Montero, JL; Passagne, I; Vian, L; Winum, JY, 2003) |
| " In melanoma specimens taken from a patient 3 h post-treatment with temozolomide, MGMT levels were reduced by 70%." | 3.69 | Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. ( Alas, LG; Belanich, M; Citron, ML; Dolan, ME; Gander, M; Kibitel, JT; Lejeune, FJ; Li, BF; Pastor, MA; Randall, T; Schold, SC; Wasserman, P; White, AB; Yarosh, DB, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| von Felbert, V | 1 |
| Bauerschlag, D | 1 |
| Maass, N | 1 |
| Bräutigam, K | 1 |
| Meinhold-Heerlein, I | 1 |
| Woitok, M | 1 |
| Barth, S | 1 |
| Hussain, AF | 1 |
| Passagne, I | 1 |
| Evrard, A | 1 |
| Winum, JY | 1 |
| Depeille, P | 1 |
| Cuq, P | 1 |
| Montero, JL | 1 |
| Cupissol, D | 1 |
| Vian, L | 1 |
| Gajewski, TF | 1 |
| Sosman, J | 1 |
| Gerson, SL | 1 |
| Liu, L | 1 |
| Dolan, E | 1 |
| Lin, S | 1 |
| Vokes, EE | 1 |
| Alvino, E | 1 |
| Castiglia, D | 1 |
| Caporali, S | 1 |
| Pepponi, R | 1 |
| Caporaso, P | 1 |
| Lacal, PM | 1 |
| Marra, G | 1 |
| Fischer, F | 1 |
| Zambruno, G | 1 |
| Bonmassar, E | 1 |
| Jiricny, J | 1 |
| D'Atri, S | 1 |
| Fontijn, D | 1 |
| Adema, AD | 1 |
| Bhakat, KK | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Boven, E | 1 |
| Belanich, M | 1 |
| Randall, T | 1 |
| Pastor, MA | 1 |
| Kibitel, JT | 1 |
| Alas, LG | 1 |
| Dolan, ME | 1 |
| Schold, SC | 1 |
| Gander, M | 1 |
| Lejeune, FJ | 1 |
| Li, BF | 1 |
| White, AB | 1 |
| Wasserman, P | 1 |
| Citron, ML | 1 |
| Yarosh, DB | 1 |
| Middleton, MR | 1 |
| Kelly, J | 1 |
| Thatcher, N | 1 |
| Donnelly, DJ | 1 |
| McElhinney, RS | 1 |
| McMurry, TB | 1 |
| McCormick, JE | 1 |
| Margison, GP | 1 |
| Christmann, M | 1 |
| Pick, M | 1 |
| Lage, H | 1 |
| Schadendorf, D | 1 |
| Kaina, B | 1 |
1 trial available for o(6)-benzylguanine and Malignant Melanoma
| Article | Year |
|---|---|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 2005 |
7 other studies available for o(6)-benzylguanine and Malignant Melanoma
| Article | Year |
|---|---|
A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Flow Cytometry; Fluorescent Dyes; Guanine; Humans; Immunot | 2016 |
Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
Topics: Antineoplastic Agents; Apoptosis; Carmustine; DNA Damage; Enzyme Inhibitors; Enzyme-Linked Immunosor | 2003 |
A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Topics: Antineoplastic Agents; Base Pair Mismatch; Dacarbazine; DNA Methylation; DNA Repair; Drug Resistance | 2006 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dac | 2007 |
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors; | 1996 |
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Topics: Antineoplastic Agents; Azacitidine; Blotting, Southern; DNA Methylation; DNA Repair; Drug Resistance | 2001 |